Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829842 | 0.96 | NPSR1 (0.31) | CYP4F2CYP4A11FFAR3BTKDGAT1 | |
| SCHEMBL23293553 | 0.94 | CYP2C19 (0.32) | CYP4F2CYP4A11FFAR3BTK | |
| SCHEMBL7884001 | 0.92 | CYP2C19 (0.31) | CYP4F2CYP4A11 | |
| SCHEMBL8880684 | 0.91 | RBP4 (0.33) | CYP4F2CYP4A11FFAR3DGAT1 | |
| Ammonia Solution, Strong SCHEMBL28588874 | 0.89 | RBP4 (0.33) | CYP4F2CYP4A11FFAR3DGAT1 | |
| SCHEMBL22927448 | 0.89 | DGAT1 (0.33) | CYP4F2CYP4A11BTKDGAT1 | |
| SCHEMBL30683839 | 0.85 | NPSR1 (0.34) | CYP4F2CYP4A11BTKDGAT1 | |
| SCHEMBL2146137 | 0.84 | OPRM1 (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL6355124 | 0.83 | NPSR1 (0.33) | CYP4F2CYP4A11DGAT1 | |
| SCHEMBL5360795 | 0.82 | USP2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| EP-4153242-B1 | PARA-AMINO-BENZYL LINKERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN CONJUGATES | SERVIER LAB (FR) | 2024-05-15 | — | — | EP | disclosed |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | LES LABORATOIRES SERVIER (FR) | 2024-02-08 | — | — | US | disclosed |
| CN-117136076-A | MCL-1 inhibitor antibody drug conjugates and methods of use | 诺华股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| EP-4251208-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| US-20230218778-A1 | PARA-AMINO-BENZYL LINKERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN CONJUGATES | LES LABORATOIRES SERVIER (FR) | 2023-07-13 | — | — | US | disclosed |
| CN-116137818-A | Para-amino-benzyl linkers, methods of making and use thereof in conjugates | 法国施维雅药厂 | 2023-05-19 | — | — | CN | disclosed |
| EP-4153242-A1 | PARA-AMINO-BENZYL LINKERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN CONJUGATES | Les Laboratoires Servier (FR) | 2023-03-29 | — | — | EP | disclosed |
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-03-16 | — | — | US | disclosed |
| US-10124069-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | GENENTECH, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| EP-3307780-A1 | ANTIBODIES AND IMMUNOCONJUGATES | Genentech, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| CN-107106700-A | Peptide simulated compound and its antibody drug conjugate | 基因泰克公司 | 2017-08-29 | — | — | CN | disclosed |
| WO-2016205176-A1 | ANTIBODIES AND IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| EP-3082875-A2 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | Genentech, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-09-29 | — | — | US | disclosed |
| WO-2015095227-A2 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-08-28 | — | — | US | disclosed |
| WO-2008095058-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2008-08-07 | — | — | WO | disclosed |
| WO-2002076968-A1 | MALONATES AS INHIBITORS OF THE ICE/CED-6 FAMILY OF CYSTEINE PROTEASES | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092679-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, BCL9, BAK1 | CYP4F2 4666/4885CYP4A11 4779/4885FFAR3 4823/4885 |
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | GLS2, SLC10A1, UGT1A1 | CYP4F2 8/4885CYP4A11 58/4885FFAR3 3170/4885 |
| US-20230081720-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD74, CD99 | CYP4F2 3887/4885CYP4A11 4814/4885FFAR3 4752/4885 |
| US-20240042051-A1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MCL1, CD58, LENG8 | CYP4F2 4168/4885CYP4A11 4847/4885FFAR3 4774/4885 |
| US-20230218778-A1 | PARA-AMINO-BENZYL LINKERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN CONJUGATES | DNPEP, PEPD, PREP | CYP4F2 421/4885CYP4A11 1045/4885FFAR3 3981/4885 |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, BCR | CYP4F2 3842/4885CYP4A11 4396/4885FFAR3 2922/4885 |
| US-10124069-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | DNPEP, LNPEP, BCR | CYP4F2 3842/4885CYP4A11 4396/4885FFAR3 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.